Categories
STUDY PURPOSE

ABBOTT INDIA Right Time To Invest Into ?

About The Company:

Abbott India Ltd is one of the largest MNC pharma companies operating in India. It is a subsidiary of Abbott Laboratories of USA. Abbott Laboratories held 75% stake in Abbott India as on 31 March 2018. The company is engaged in the discovery development manufacture and marketing of pharmaceutical diagnostic nutritional and hospital products. They are having their presence in both OTC drugs and formulations. Their manufacturing facilities are located at Verna in Goa. The company’s global products include Brufen Prothiaden Thyronorm and Leptos.The company has four divisions. The Primary Care division markets products in the areas of pain management and gastroenterology. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid obesity diabetes and benign prostatic hyperplasia. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments. Hospital Care offers products in the field of anesthesiology and neonatology such as Forane Sevorane and Survanta.Abbott India Ltd was originally incorporated on August 22 1944 as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1 1971 thereafter to Boots Pharmaceuticals Ltd on January 1 1991. In October 31 1995 the name was changed to Knoll Pharmaceuticals Ltd and in July 1 2002 they got their present name Abbott India Ltd. In the year 2002 the company sold their Jejuri Undertakings together with assets and liabilities as a going concern. In the year 2003 the company’s wholly owned subsidiary company Lenbrook Pharmaceuticals Ltd was amalgamated with the company.In the year 2004 the company started the production of Capsules with the capacity of 27 Millions Nos. In the year 2005 they further increased the capacity to 56 Million Nos. Also they started a new project of producing Nutritional Products with the installed capacity of 600 Tonnes. In the year 2006 the company increased the production capacity of Tablets by 236 Million Nos to 686 Million Nos. In the year 2008 they further increased the production capacity of Tablets by 769 million Nos to 1455 million Nos. They launched Digene Total buffered pantoprazole tablet for quick and sustained antacid action and Brugel a novel formulation for sprains and strains. Also they launched Thyronorm 150 Digene Sugar Free Tablet and Gel during the year.The Buy-Back Committee of the Board of Directors of Abbott India at its meeting held on 9 July 2008 approved buy-back of 7.97 lakh fully paid-up equity shares of the company via the tender offer method at a price of Rs 630 per share. The Board of Directors of Abbott India Ltd. and Solvay Pharma India Ltd. at their respective meetings held on 24 November 2010 unanimously approved the draft scheme for the amalgamation of Solvay Pharma India into Abbott India under sections 391 to 394 of the Companies Act 1956. The swap ratio for the merger recommended is 2:3. In other words every two shares of the Solvay Pharma India Ltd. will entitle their holder to three shares of Abbott India Ltd. On 17 May 2011 Abbott Capital India Limited sold 2.24 lakh shares out of its total holding of 94.28 lakh shares in Abbott India Limited by way of an on market transaction. As a consequence the promoter shareholding in Abbott India Limited after the merger of Solvay Pharma India Limited into Abbott India Limited will be 74.98%. Therefore the listing of shares issued pursuant to the share exchange ratio in the merger will not result in the public shareholding in Abbott India Limited falling below 25% as required under Clause 40A of the Listing Agreement. On 7 September 2011 Abbott India completed the allotment of 75.74 lakh equity shares to the shareholders of Solvay Pharma India Ltd in the ratio of 2:3 in terms of the Scheme of Amalgamation of Solvay Pharma India Ltd with Abbott India. The Board of Directors of Abbott India at its meeting held on 3 June 2013 decided to defer the proposal received by the company for the sale and transfer of or other appropriate restructuring of the proprietary pharmaceuticals division (PPD) of the company.

Products of Company :

Abbott in India develops and distributes over 600 products for healthcare professionals that promote health and well-being for Indians in all stages of life. Search by all products, business area or pharmaceutical therapy area below.

In total pharmaceutical business covers 90 per cent of therapies in India their goals are to increase the depth and breadth of the medicines They offer in these areas, ensure broader reach to people in India and continue to launch improved medicines that make it better or easier for people to get healthy.

My Analysis:  Abbott India Now Trading at Low Valuations Below 200 DMA at 14,300. Which is Best Time To Invest for Short Term as Well as Long Term .So its best time to invest in Such a Huge Potential Stock.

 Expected Targets for Short Term as 16,500 below one Year.

For Short Term Stop loss at 12,800 Weekly Closing Basis .

Long Term Target of Rs.20500 – 22,800/- in 3- 5 Years of Time Frame .

Disclaimer: I am Not a SEBI REGISTERED ANALYST. This Website & Its Owner, Creator & Contributor is Neither a Research Analyst nor an Investment Advisor and Expressing Option Only as an Investor in Indian Equities. All trading strategies are used at your own risk. He/ She are Not Responsible for any Loss a Rising out of any Information, Post or Opinion Appearing on this Website. Investors are advised to do Own Due Diligence or Consult Financial Consultant before acting on Such Information. Author of this Website not providing any Paid Service and not Sending Bulk mails/SMS to Anyone. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Investment/Trading in securities Market is subject to market risk.

Categories
PENNY STOCKS/PENNY SHARES STUDY PURPOSE

Dark Horse Stock In Cement Sector Stock ?

About Company :

​Today, our capacity stands at 1.20 Million Tons per Annum housing a Fully Automatic Modern Cement Plant. We are an ISO 9001ISO 14001 & OHSAS 18000 certified plant. In addition to this we are amongst the earliest Accredited Company’s awarded with the prestigious license from American Petroleum Institute (API) for the manufacturing of Oil Well Cement – API 10A Class G HSR Cement.

We are one of India’s pioneer in manufacturing Cement. We started our operations in India in 1944 at the coastal township of Digvijaygram (Sikka) in Jamnagar District of Gujarat. Since 2019, we are a part of True North formerly known as India Value Fund Advisers (IVFA).

SHREE DIGVIJAY CEMENT CO. LTD has been a unique trendsetter in providing superior quality of Ordinary & Special Portland Cement. We employ approximately 300 Employees and have a Gujarat-wide network of over 1,000 Channel Partners selling our Cement under the Brand Name “KAMAL CEMENT“.

We offer unique combination of product quality along with Customer Tailored Logistics solutions offered thru combination of Road, Railways & Captive Sea port. Our Captive Sea port can easily harbour and handle 3,000 to 5,000 DWT vessels along the jetty. Safe anchorage for 5,000 to 35,000 DWT vessels are available at a distance of 5 Kms from the port / wharf site. For safe anchorage of 50,000 – 100,000 DWT vessels 20-25 meters of water is available at a distance of 10 Kms from the port site.

SHREE DIGVIJAY CEMENT CO. LTD is also well connected by Road and Rail. The nearest airport is Jamnagar airport which is 30 Kms from the plant. Its plant, mines and township visibly demonstrate successful endeavors in Mines Rehabilitation, Water Management and Environmental Restoring Activities.​

Our commitment to sustainable development, our high ethical standards in Business dealings and our on-going efforts in community welfare programmes have always been appreciated. We are one of the key exporters of Cement and Cement Clinker throughout the world for which we have received the Certificate of Honour of Export House from Hon’ble President of India.​

KAMAL CEMENT standing strong since past seven decades carves out the long proud legacy of building the nation by manufacturing Superior Quality Cement. Today, it is one of the most experienced cement producing companies in India.

The competitive edge is exhibited through constant technological upgradations and its commitment to producing a perfect quality cement that is industry focused. KAMAL CEMENT goes thru best Quality Control checks in its Internationally as well as Nationally Accredited (API & BIS) Quality Control Laboratory.

The EMS (ISO 9001, 14001 & 18001) certified KAMAL CEMENT manufacturing facility is accredited with International Standard Quality Control Systems that meet the most advanced methods of Consistent Quality Cement production. Fully computerized and dynamically monitored production processes ensures consistency in Quality of every finest grain of cement, making Kamal Cement the most preferred cement.

PPC Cement

KAMAL PPC Cement is a top quality Portland Pozzolona Cement manufactured with regards to IS 1489 (Part 1). This revolutionary product has top quality Pozzolona particles to give higher reactivity.

The High Reactive Silica (HRS) in the cement helps to give most optimized workability with low Heat of Hydration & Low Water / Cement Ratio to guarantee Denser Concrete for Durability, Strength and Longest Service life to your Dream Constructions.

OPC Cement

KAMAL OPC Cement is a 53 Grade Portland Cement manufactured with regards to IS 269 : 2015. This Superior Quality Cement comes with High Compressive Strength and low C3A content which is ideal for all major RCC and PCC works.

KAMAL OPC Cement’s low Magnesia and negligible Chlorides content makes the your Concrete Crack & Corrosion Resistant, ensuring ever-lasting protection to your Dream Structures.

SRPC Cement

KAMAL SRPC Cement is Sulphate Resisting Portland Cement manufactured with regards to IS 12330. This Super Quality Premium Cement comes with High Sulphate Resistivity Composition to give Total Protection from the most corrosive Sulphate attacks of Moisture & Alkaline Air in the Environment.

KAMAL SRPC Cement is the most ideal Cement for Coastal Constructions and all PCC & RCC Under-Ground Constructions making your Foundations stand Rock Solid.

OIL WELL Cement

Oil Well Cement a key specialty product of SHREE DIGVIJAY CEMENT Co. LTD. Our Oil Well Cement is amongst the best cement available for cementing offshore and onshore wells under high pressure and temperature. Kamal Cement’s Oil Well Cement is a HSR Cement . This is premium Quality Cement for the Oil & Gas Industry ideal for all Off-Shore & On-Shore Oil Well Cementing solutions.

SHREE DIGVIJAY CEMENT CO. LTD is India’s largest producer of Oil Well Cement with close to 30 years of expertise in manufacturing. Our Oil Well Cement comes with Customer Tailored Supply Chain requirements thereby making us your most preferred partners in Oil Extraction.

Cement Ka Sardar

Cement Ka Sardar is a special cement through which the desire of a customer gets full-filled wherein they dream of building their houses with a special premium quality cement to have the best of CRACK-FREE Concrete. This premium product comes with 6 Special benefits which include:

  • High Early Strength
  • Quick Setting Time
  • Superior Cohesion
  • Resistant to Chemical Attack
  • High Durability
  • Eco-Friendly Green Cement

These 6 special features make the product – Cement ka Sardar as an active contributor to providing a shield of protection against the adverse Climate Impact on the concrete. And the Individual House Building Customers get a durable construction in all the years to come.

My View: Company Management Changed and Expecting Dividend Might Be Possible In Coming Months Also . And there is Huge Demand for construction Sector in Coming Years Also .

From Cmp 36.50 We can Expect Prices Can Double and Can Even Triple in Coming Years Also .

Target : 72.50 – 111 ++ Possible in Next 2 Years to 4 Years time Frame – STUDY PURPOSES ONLY.

Disclaimer: I am Not a SEBI REGISTERED ANALYST. This Website & Its Owner, Creator & Contributor is Neither a Research Analyst nor an Investment Advisor and Expressing Option Only as an Investor in Indian Equities. All trading strategies are used at your own risk.

He/ She are Not Responsible for any Loss a Rising out of any Information, Post or Opinion Appearing on this Website. Investors are advised to do Own Due Diligence or Consult Financial Consultant before acting on Such Information.

Author of this Website not providing any Paid Service and not Sending Bulk mails/SMS to Anyone. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted. Investment/Trading in securities Market is subject to market risk. This is my personal thoughts on this company and not at all a buy recommendation. Do own due diligence /consult a SEBI registered advisor before any action.